04-05-2016 - AB ANALITICA and CURTIN UNIVERSITY AUSTRALIA - Conference Poster

Investigation of Novel Biomarkers for Pancreatic Cancer

Aikaterini Emmanouilidi1, Dino Paladin2, Marco Falasca1

1 Metabolic Signalling Group, School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Australia, 2 AB Analitica, Padova, Italy


Pancreatic cancer (PaCa) is among the deadliest cancers with only 3% of diagnosed patients given a 5-year survival rate. It is diagnosed at a late stage mostly due to the lack of appropriate biomarkers for early diagnosis. CA19.9 is a currently used biomarker but does not exhibit the desirable level of specificity and sensitivity. In order to identify novel potential biomarkers we used a lipidomics-based approach and focused our attention to lysophospholipids and enzymes involved in their metabolism as suitable novel PaCa biomarker candidates. We are currently investigating pancreatic cancer cell lines compared to normal pancreatic lines by lipid isolation from PaCa cell lines supernatant, and transgenic mouse models generating the full PanIN lineage, and blood and urine samples from PaCa patients and healthy controls. Our group has previously shown that Ras-transformed cells exhibit elevated lysophospholipids release able to stimulate cancer autocrine cell proliferation. Moreover, our group has suggested an autocrine loop in which ABCC transporters efflux lysophosphatidylinositol (LPI) which in turn promotes cell proliferation via GPR55 activation. Our goal is to determine whether there is a lipid signature unique for PaCa, and make a comparison with other cancer types, such as ovarian and prostate cancer. Determining an effective biomarker can replace costly and prohibitive for routine screening, technologies.